Skip to main
  1. Stocks
  2. IGC Pharma Inc
  3. Forecast
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is positioned favorably because its lead asset, IGC-AD1, has already delivered a clinically and statistically significant reduction in agitation versus placebo in March 2024, while also showing preclinical potential against plaques and tangles in Alzheimer’s cell lines. The Phase 2 CALMA trial has reached its original enrollment target of 146 patients in August, is within 6 randomizations of closure, and is expected to deliver topline data in Q4 2026, creating a clear near-term catalyst path alongside the planned AI beta program. With 5 Alzheimer’s candidates, 2 later-stage assets, and a market opportunity framed as billion-dollar potential in a disease with no known cure, the fundamentals support a high-risk, high-reward bullish outlook.

Bears say

IGC Pharma is a highly speculative biotech name whose value depends on unproven cannabinoid-based formulations, including investigational assets for Alzheimer’s disease, that have only shown potential in cell lines rather than validated clinical outcomes. The thesis is weakened by substantial balance sheet and liquidity risk, along with the possibility that product candidates may fail on safety, efficacy, or regulatory approval, which would prevent commercialization and reimbursement. Even if development progresses, the company still faces intense competition, shifting macroeconomic conditions, weak biotech investor sentiment, and changing consumer or government healthcare priorities, all of which could pressure fundamental performance.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IGC Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.

IGC Analyst Forecast & Price Prediction

Get the latest IGC stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IGC

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IGC Pharma Inc (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IGC Pharma Inc (IGC)


IGC Analyst Forecast & Price Prediction

Get the latest IGC stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IGC

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IGC stock data and trends